Fremanezumab for episodic migraine in children and adolescents: the evolving landscape of CGRP-targeted therapies

Paige Kalika, Teshamae S. Monteith · 2026

Read Fremanezumab for episodic migraine in children and adolescents: the evolving landscape of CGRP-targeted therapies by Paige Kalika, Teshamae S. Monteith (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13655850.txt.

Description

Paige Kalika and Teshamae Monteith review migraine prevention drugs for children and teens, focused on fremanezumab. Their twenty twenty-six paper places the drug in the growing class of CGRP-targeted therapies. Migraine is the top nerve cause of disability in youth worldwide.

Child trials in this field have lagged, and placebo responses often run high. Those high responses can match the study drug and cloud the results. The authors survey the wider set of preventive options, drug and non-drug alike. They weigh where antibody drugs that block the CGRP path fit for episodic migraine in youth. Readers get a clear map of a fast-changing care landscape.

Catalog record

CREATORPaige Kalika, Teshamae S. Monteith
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE19 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13655850

Browse the full library · About the Tower of Babel